These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 35983617)

  • 1. Does India need a new pharmaceutical policy? Examining the implications of the drug price control order.
    Kumar R; Joshi MM; Palod RJ; Dharmagadda S
    Int J Health Plann Manage; 2022 Nov; 37(6):3028-3038. PubMed ID: 35983617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies.
    Acosta A; Ciapponi A; Aaserud M; Vietto V; Austvoll-Dahlgren A; Kösters JP; Vacca C; Machado M; Diaz Ayala DH; Oxman AD
    Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD005979. PubMed ID: 25318966
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmaceutical Policy Reforms to Regulate Drug Prices in the Asia Pacific Region: The Case of Australia, China, India, Malaysia, New Zealand, and South Korea.
    Hasan SS; Kow CS; Dawoud D; Mohamed O; Baines D; Babar ZU
    Value Health Reg Issues; 2019 May; 18():18-23. PubMed ID: 30414506
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimal price regulations in international pharmaceutical markets with generic competition.
    Geng D; Saggi K
    J Health Econ; 2020 May; 71():102315. PubMed ID: 32273046
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endogenous versus exogenous generic reference pricing for pharmaceuticals.
    Antoñanzas F; Juárez-Castelló CA; Rodríguez-Ibeas R
    Int J Health Econ Manag; 2017 Dec; 17(4):413-432. PubMed ID: 28508248
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Implications of national tax policy on local pharmaceutical production in a southwestern state nigeria - qualitative research for the intersection of national pharmaceutical policy on health systems development.
    Obembe TA; Adenipekun AB; Morakinyo OM; Odebunmi KO
    BMC Health Serv Res; 2022 Feb; 22(1):264. PubMed ID: 35220971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of European pharmaceutical price regulation on generic price competition: a review.
    Puig-Junoy J
    Pharmacoeconomics; 2010; 28(8):649-63. PubMed ID: 20515079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Generic drug prices and policy in Australia: room for improvement? a comparative analysis with England.
    Mansfield SJ
    Aust Health Rev; 2014 Feb; 38(1):6-15. PubMed ID: 24480618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug price transparency initiative: A scoping review.
    Ahmad NS; Makmor-Bakry M; Hatah E
    Res Social Adm Pharm; 2020 Oct; 16(10):1359-1369. PubMed ID: 31987771
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Costs of paying higher prices for equivalent effects on the Pharmaceutical Benefits Scheme.
    Karnon J; Edney L; Sorich M
    Aust Health Rev; 2017 Mar; 41(1):1-6. PubMed ID: 26954612
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Risk sharing methods in middle income countries].
    Inotai A; Kaló Z
    Acta Pharm Hung; 2012; 82(1):43-52. PubMed ID: 22570986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of South Korea's new drug-pricing policy on market competition among off-patent drugs.
    Kwon HY; Kim H; Godman B; Reich MR
    Expert Rev Pharmacoecon Outcomes Res; 2015; 15(6):1007-14. PubMed ID: 26394767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of prices paid by low-income countries - how price sensitive is government demand for medicines?
    Srivastava D; McGuire A
    BMC Public Health; 2014 Jul; 14():767. PubMed ID: 25073407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reference pricing with endogenous generic entry.
    Brekke KR; Canta C; Straume OR
    J Health Econ; 2016 Dec; 50():312-329. PubMed ID: 27350294
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmaceutical pricing: an empirical study of market competition in Chinese hospitals.
    Wu J; Xu J; Liu G; Wu J
    Pharmacoeconomics; 2014 Mar; 32(3):293-303. PubMed ID: 24190661
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The pan-Canadian Tiered Pricing Framework and Chinese National Volume-Based Procurement: A comparative study using Donabedian's structure-process-outcome framework.
    Wang Q; Liu S; Nie Z; Zhu Z; Fu Y; Zhang J; Wei X; Yang L; Wei X
    J Glob Health; 2023 Nov; 13():04137. PubMed ID: 37947028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. European healthcare policies for controlling drug expenditure.
    Ess SM; Schneeweiss S; Szucs TD
    Pharmacoeconomics; 2003; 21(2):89-103. PubMed ID: 12515571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Access to Cardiovascular Disease and Hypertension Medicines in Developing Countries: An Analysis of Essential Medicine Lists, Price, Availability, and Affordability.
    Husain MJ; Datta BK; Kostova D; Joseph KT; Asma S; Richter P; Jaffe MG; Kishore SP
    J Am Heart Assoc; 2020 May; 9(9):e015302. PubMed ID: 32338557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [An analysis of the pharmaceuticals market in Vietnam].
    Simonet D
    Sante; 2001; 11(3):155-60. PubMed ID: 11641078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies.
    Aaserud M; Dahlgren AT; Kösters JP; Oxman AD; Ramsay C; Sturm H
    Cochrane Database Syst Rev; 2006 Apr; (2):CD005979. PubMed ID: 16625648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.